| abstract |
Disclosed are compounds of formula (I), wherein the substituents are as defined in the specification. The compounds modulate the activity of the farnesoid X receptor, and are useful in treating, preventing, or ameliorating hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, dyslipidemia, lipodystrophy, atherosclerosis, atherosclerotic disease, atherosclerotic disease events, atherosclerotic cardiovascular disease, Syndrome X, diabetes mellitus, type II diabetes, insulin insensitivity, hyperglycemia, cholestasis and obesity. |